

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-Q

Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
For the quarterly period ended March 31, 2016 or

Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
For the transition period from \_\_\_\_\_ to \_\_\_\_\_

001-9731  
(Commission file No.)

ARRHYTHMIA RESEARCH TECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State or other jurisdiction of incorporation or organization)

72-0925679

(I.R.S. employer identification no.)

25 Sawyer Passway  
Fitchburg, Massachusetts 01420  
(Address of principal executive offices and zip code)

(978) 345-5000  
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated filer  Accelerated filer  Non-Accelerated filer  Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of May 12, 2016 there were 2,816,639 shares of the Company's common stock outstanding.

---

---

Table of Contents

**Arrhythmia Research Technology, Inc.**  
**TABLE OF CONTENTS**

	<b><u>PART I - CONDENSED FINANCIAL STATEMENTS</u></b>	<b>3</b>
<u>Item 1</u>	<u>Condensed Consolidated Financial Statements</u>	<b>3</b>
	<u>Condensed Consolidated Balance Sheets</u>	<b>3</b>
	<u>Condensed Consolidated Statements of Operations</u>	<b>4</b>
	<u>Condensed Consolidated Statements of Cash Flows</u>	<b>5</b>
	<u>Notes to the Condensed Consolidated Financial Statements</u>	<b>6</b>
<u>Item 2</u>	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	<b>12</b>
<u>Item 3</u>	<u>Quantitative and Qualitative Disclosures about Market Risk</u>	<b>17</b>
<u>Item 4</u>	<u>Controls and Procedures</u>	<b>17</b>
	<b><u>PART II - OTHER INFORMATION</u></b>	<b>18</b>
<u>Item 6</u>	<u>Exhibit Index</u>	<b>18</b>
	<u>SIGNATURES</u>	<b>20</b>

[Table of Contents](#)**PART I - CONDENSED FINANCIAL STATEMENTS****Item 1. Condensed Consolidated Financial Statements (unaudited)**

**Arrhythmia Research Technology, Inc. and Subsidiaries**  
Condensed Consolidated Balance Sheets  
(unaudited)

	March 31, 2016	December 31, 2015
<b>Assets</b>		
<b>Current assets:</b>		
Cash and cash equivalents	\$ 220,299	\$ 272,291
Trade accounts receivable, net of allowance for doubtful accounts of \$60,000 at March 31, 2016 and December 31, 2015	3,339,549	2,798,353
Inventories	2,115,071	2,118,712
Prepaid expenses and other current assets	637,529	614,129
<b>Total current assets</b>	<b>6,312,448</b>	<b>5,803,485</b>
Property, plant and equipment, net	6,638,327	6,626,069
Assets held for sale, net	665,000	665,000
Intangible assets, net	18,206	18,645
Other assets	239,480	268,835
<b>Total assets</b>	<b>\$ 13,873,461</b>	<b>\$ 13,382,034</b>
<b>Liabilities and Shareholders' Equity</b>		
<b>Current liabilities:</b>		
Equipment line of credit, current portion	51,299	35,718
Term notes payable, current portion	596,255	589,635
Subordinated promissory notes	480,056	473,135
Accounts payable	1,671,531	1,553,388
Accrued expenses and other current liabilities	374,769	275,777
Customer deposits	359,662	93,407
Deferred revenue, current	258,543	272,837
<b>Total current liabilities</b>	<b>3,792,115</b>	<b>3,293,897</b>
<b>Long-term liabilities:</b>		
Revolving line of credit, non-current portion	1,981,495	1,511,495
Equipment line of credit, non-current portion	285,551	301,132
Term notes payable, non-current portion	969,209	1,120,652
Deferred revenue, non-current	280,279	272,181
<b>Total long-term liabilities</b>	<b>3,516,534</b>	<b>3,205,460</b>
<b>Total liabilities</b>	<b>7,308,649</b>	<b>6,499,357</b>
<b>Commitments and Contingencies</b>		
<b>Shareholders' equity:</b>		
Preferred stock, \$0.001 par value; 2,000,000 shares authorized, none issued	—	—
Common stock, \$0.01 par value; 10,000,000 shares authorized; 3,926,491 issued, 2,816,639 outstanding at March 31, 2016 and 3,926,491 issued, 2,801,639 outstanding at December 31, 2015	39,265	39,265
Additional paid-in-capital	11,406,887	11,381,536
Treasury stock at cost, 1,109,852 shares at March 31, 2016 and 1,124,852 shares at December 31, 2015	(3,028,564)	(3,069,496)
Accumulated deficit	(1,852,776)	(1,468,628)
<b>Total shareholders' equity</b>	<b>6,564,812</b>	<b>6,882,677</b>
<b>Total liabilities and shareholders' equity</b>	<b>\$ 13,873,461</b>	<b>\$ 13,382,034</b>

*See accompanying notes to condensed consolidated financial statements.*

[Table of Contents](#)

**Arrhythmia Research Technology, Inc. and Subsidiaries**  
**Condensed Consolidated Statements of Operations**  
**(unaudited)**

	Three Months Ended	
	March 31,	
	2016	2015
<b>Net sales</b>	\$ 4,983,281	\$ 5,858,342
<b>Cost of sales</b>	4,298,162	5,061,946
Gross profit	685,119	796,396
<b>Selling and marketing</b>	293,346	257,972
<b>General and administrative</b>	690,635	648,227
<b>Research and development</b>	25,843	92,561
Total operating expenses	1,009,824	998,760
Net loss from continuing operations	(324,705)	(202,364)
<b>Other expense:</b>		
Interest expense	(60,220)	(65,693)
Other income, net	777	13,509
Total other expense, net	(59,443)	(52,184)
<b>Loss from continuing operations before income taxes</b>	(384,148)	(254,548)
<b>Income tax provision</b>	—	—
Loss from continuing operations	(384,148)	(254,548)
<b>Discontinued Operations:</b>		
Income from discontinued operations, net of tax provision of \$0 for the three months ended March 31, 2016 and 2015	—	362,610
<b>Net income (loss)</b>	\$ (384,148)	\$ 108,062
Earnings (loss) per share - basic		
Continuing operations	\$ (0.14)	\$ (0.09)
Discontinued operations	—	0.13
Earnings (loss) per share - basic	\$ (0.14)	\$ 0.04
Earnings (loss) per share - diluted		
Continuing operations	\$ (0.14)	\$ (0.09)
Discontinued operations	—	0.13
Earnings (loss) per share - diluted	\$ (0.14)	\$ 0.04
Weighted average common shares outstanding - basic	2,816,144	2,778,935
Weighted average common shares outstanding - diluted	2,816,144	2,877,599

*See accompanying notes to condensed consolidated financial statements.*

[Table of Contents](#)

**Arrhythmia Research Technology, Inc. and Subsidiaries**  
**Condensed Consolidated Statements of Cash Flows**  
**(unaudited)**

	Three Months Ended March 31,	
	2016	2015
<b>Cash flows from operating activities:</b>		
Net income (loss)	\$ (384,148)	\$ 108,062
Income from discontinued operations	—	(362,610)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:		
(Gain) loss on sale of property, plant and equipment	—	(11,029)
Depreciation and amortization	361,440	356,382
Non-cash interest expense	6,921	6,921
Change in allowance for doubtful accounts	—	3,000
Share-based compensation expense	15,133	7,186
Changes in operating assets and liabilities:		
Accounts receivable	(541,196)	(476,322)
Inventories	3,641	(11,947)
Prepaid expenses and other current assets	(23,400)	(96,785)
Other non-current assets	29,355	168,405
Accounts payable	118,143	411,677
Accrued expenses and other current liabilities	350,954	357,803
Other non-current liabilities	8,097	(185,641)
Net cash provided by (used in) operating activities	(55,060)	275,102
<b>Cash flows from investing activities:</b>		
Purchases of property, plant and equipment	(373,259)	(242,390)
Proceeds from sale of property, plant and equipment	—	17,000
Cash paid for patents and trademarks	—	(1,057)
Net cash provided by (used in) investing activities	(373,259)	(226,447)
<b>Cash flows from financing activities:</b>		
Proceeds from (payments on) revolving line of credit, net	470,000	250,000
Payments on term notes payable	(144,823)	(120,551)
Proceeds from stock option exercises	51,150	3,880
Net cash provided by (used in) financing activities	376,327	133,329
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>(51,992)</b>	<b>181,984</b>
<b>Cash and cash equivalents, beginning of period</b>	<b>272,291</b>	<b>209,398</b>
<b>Cash and cash equivalents, end of period</b>	<b>220,299</b>	<b>391,382</b>

	Three Months Ended March 31,	
	2016	2015
<i>Supplemental Cash Flow Information</i>		
Cash paid for interest	\$ 55,579	\$ 53,705

*See accompanying notes to condensed consolidated financial statements.*

**Arrhythmia Research Technology, Inc. and Subsidiaries**  
**Period Ended March 31, 2016**

Notes to the Condensed Consolidated Financial Statements (unaudited)

**1. Basis of Presentation**

The consolidated financial statements (the "financial statements") include the accounts of Arrhythmia Research Technology, Inc.<sup>®</sup> ("ART") and its subsidiary, Micron Products, Inc.<sup>®</sup> ("Micron" and together with ART, the "Company"). ART discontinued operations of its wholly-owned Pennsylvania subsidiary, RMDDxUSA Corp. ("RMDDxUSA") and that subsidiary's Prince Edward Island subsidiary, RMDDx Corporation ("RMDDx" and collectively with RMDDxUSA, "WirelessDx") in the third quarter of 2012. In May 2014, RMDDxUSA filed for bankruptcy and the Chapter 7 discharge order was issued on March 20, 2015 and the case was closed (see Note 10). The WirelessDx results are presented herein as discontinued operations. All intercompany balances and transactions have been eliminated in consolidation.

The unaudited interim condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Accordingly, certain information and footnote disclosures normally included in complete financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") have been omitted pursuant to such rules and regulations. These financial statements and related notes should be read in conjunction with the consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2015 filed with the SEC on March 10, 2016.

The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. The Company's balance sheet at December 31, 2015 has been derived from the audited financial statements at that date, but does not include all the information and footnotes required by GAAP for complete financial statements.

The information presented reflects, in the opinion of the management of the Company, all adjustments necessary for a fair presentation of the financial results for the interim periods presented. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

**2. Earnings per Share ("EPS")**

Basic earnings (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding. The computation of diluted earnings (loss) per share is similar to the computation of basic earnings (loss) per share except that the denominator is increased to include the average number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. In addition, the numerator is adjusted for any changes in net income (loss) that would result from the assumed conversions of those potential shares.

[Table of Contents](#)

**Arrhythmia Research Technology, Inc. and Subsidiaries**  
**Period Ended March 31, 2016**

Notes to the Condensed Consolidated Financial Statements (unaudited)

The following table presents the calculation of both basic and diluted EPS:

	Three Months Ended March 31,	
	2016	2015
Income (loss) from continuing operations	\$ (384,148)	\$ (254,548)
Income from discontinued operations, net of tax	—	362,610
Net income (loss) available to common shareholders	\$ (384,148)	\$ 108,062
Basic EPS:		
Weighted average common shares outstanding	2,816,144	2,778,935
Earnings (loss) per share - basic		
Continuing operations	\$ (0.14)	\$ (0.09)
Discontinued operations	—	0.13
Consolidated basic EPS	\$ (0.14)	\$ 0.04
Diluted EPS:		
Weighted average common shares outstanding	2,816,144	2,778,935
Assumed conversion of net common shares issuable under stock option plans	—	62,164
Assumed conversion of net common shares issuable under warrants	—	36,500
Weighted average common and common equivalent shares outstanding, diluted	2,816,144	2,877,599
Earnings (loss) per share - diluted		
Continuing operations	\$ (0.14)	\$ (0.09)
Discontinued operations	—	0.13
Consolidated diluted EPS	\$ (0.14)	\$ 0.04

### 3. Inventories

Inventories consist of the following:

	March 31, 2016	December 31, 2015
Raw materials	\$ 744,320	\$ 775,427
Work-in-process	397,850	265,113
Finished goods	972,901	1,078,172
Total	\$ 2,115,071	\$ 2,118,712

Silver included in raw materials, work-in-process and finished goods inventory had an estimated cost of \$297,851 and \$313,738 as of March 31, 2016 and December 31, 2015, respectively.

[Table of Contents](#)

**Arrhythmia Research Technology, Inc. and Subsidiaries**  
**Period Ended March 31, 2016**

Notes to the Condensed Consolidated Financial Statements (unaudited)

**4. Property, Plant and Equipment, net**

Property, plant and equipment, net consist of the following:

	Asset Lives (in years)	March 31, 2016	December 31, 2015
Machinery and equipment	3 to 15	\$ 15,285,910	\$ 15,168,377
Building and improvements	5 to 25	3,978,387	3,978,387
Vehicles	3 to 5	90,713	90,713
Furniture, fixtures, computers and software	3 to 5	1,439,381	1,437,692
Construction in progress		936,106	682,069
Total property, plant and equipment		21,730,497	21,357,238
Less: accumulated depreciation		(15,092,170)	(14,731,169)
Property, plant and equipment, net		\$ 6,638,327	\$ 6,626,069

For the three months ended March 31, 2016 and 2015, the Company recorded depreciation expense of \$361,001 and \$355,388, respectively.

On December 4, 2015, the Company entered into a Letter of Intent to sell its two unoccupied buildings, with a total of approximately 52,000 square feet, and land, at its Fitchburg, Massachusetts campus. On January 13, 2016, the Company entered into a Purchase and Sale Agreement to sell these two buildings which have been classified as Assets Held for Sale at March 31, 2016 and December 31, 2015. The carrying value of the properties (\$665,000) approximated the fair value less the cost to sell. The Company expects the sale of the properties to be completed by the end of 2016 and does not expect any material impact on the statement of operations.

**5. Intangible Assets, net**

The Company assesses the impairment of long-lived assets and intangible assets with finite lives annually or whenever events or changes in circumstances indicate that the carrying value may not be fully recoverable. For the three months ended March 31, 2016 and 2015, no impairment was required.

Intangible assets consist of the following:

	Estimated Useful Life (in years)	March 31, 2016			December 31, 2015		
		Gross	Accumulated Amortization	Net	Gross	Accumulated Amortization	Net
Patents and trademarks	10	\$ 26,626	8,420	\$ 18,206	\$ 26,626	\$ 7,981	\$ 18,645
Total intangible assets		\$ 26,626	\$ 8,420	\$ 18,206	\$ 26,626	\$ 7,981	\$ 18,645

For the three months ended March 31, 2016 and 2015, the Company recorded amortization expense of \$439 and \$994, respectively.



**Arrhythmia Research Technology, Inc. and Subsidiaries**  
**Period Ended March 31, 2016**

Notes to the Condensed Consolidated Financial Statements (unaudited)

## 6. Debt

The following table sets forth the items which comprise debt for the Company:

	March 31, 2016	December 31, 2015
<b>Revolving line of credit</b>	\$ 1,981,495	\$ 1,511,495
<b>Equipment line of credit</b>	\$ 336,850	\$ 336,850
<b>Subordinated promissory notes</b>	\$ 480,056	\$ 473,135
<b>Term notes payable:</b>		
Commercial term loan	\$ 638,199	\$ 714,175
Equipment term loans	824,993	879,898
Equipment notes	102,272	116,214
<b>Total term notes payable</b>	\$ 1,565,464	\$ 1,710,287
<b>Total Debt</b>	\$ 4,363,865	\$ 4,031,767

### Bank Debt

The revolving line of credit (the "revolver"), commercial term loan, two equipment term loans and an equipment line of credit are all under the terms of a multi-year credit facility with a bank as detailed below. The debt is secured by substantially all assets of the Company with the exception of real property.

#### *Revolver*

The revolver provides for borrowings up to 80% of eligible accounts receivable and 50% of eligible raw materials inventory. The interest rate on the revolver is calculated at the bank's prime rate plus 0.25% (3.75% at March 31, 2016). The revolver has a maturity date of June 2017. Amounts available to borrow under the revolver are \$264,731 at March 31, 2016.

#### *Commercial term loan*

The commercial term loan has a five year term with a maturity date in March 2018. The interest rate on the loan is a fixed 4.25% per annum, and requires monthly payments of approximately \$28,000.

#### *Equipment line of credit and equipment term loans*

On March 29, 2013, the Company entered into an equipment line of credit that allowed for advances of up to \$1.0 million and included a one-year draw period during which payments were interest only. The draw period ended March 29, 2014 and the then outstanding balance on the equipment line of credit of \$740,999 was converted to an equipment term loan with a five-year term, maturing on of March 29, 2019. The equipment term loan requires monthly payments of approximately \$14,000, consisting of principal and interest at a fixed rate of 4.65%.

On June 26, 2014, the Company entered into an equipment line of credit that allowed for advances of up to \$1.0 million and included a one-year draw period during which payments were interest only. The draw period ended June 26, 2015 and the then outstanding balance on the equipment line of credit of \$415,785 was converted to an equipment term loan with a five-year term, maturing on of June 26, 2020. The equipment term loan requires monthly payments of approximately \$8,000, consisting of principal and interest at a fixed rate of 4.67%.

On June 19, 2015, the Company entered into a new equipment line of credit for \$1.0 million under the Company's multi-year credit facility. At March 31, 2016, the Company has drawn \$336,850 on the new equipment line of credit. The term of this equipment line of credit is six years, maturing on June 19, 2021, inclusive of a maximum one-year draw period. Repayment shall consist of monthly interest only payments, equal to the bank's prime rate plus 0.25% as to each advance commencing on the date of the loan through the earlier of: (i) one year from the date of the loan or (ii) the date upon which the equipment line of credit is fully advanced (the "Conversion Date"). On the Conversion Date, principal and interest payments will be due and payable monthly in an amount sufficient to pay the loan in full based upon an amortization schedule commensurate with the remaining term of the loan.

**Arrhythmia Research Technology, Inc. and Subsidiaries**  
**Period Ended March 31, 2016**

Notes to the Condensed Consolidated Financial Statements (unaudited)

Other Debt

*Equipment notes*

In January 2013, the Company entered into two equipment notes totaling \$272,500 with a financing company to acquire production equipment. The notes bear interest at the fixed rate of 4.66% and require monthly payments of principal and interest of approximately \$5,000 over a five year term maturing in January 2018.

*Subordinated promissory notes*

In December 2013, the Company completed a private offering in which the Company sold an aggregate of \$500,000 in subordinated promissory notes. The notes are unsecured and require quarterly interest-only payments at a rate of 10% per annum for the first two years, increasing to 12% per annum in December 2015. The notes mature in December 2016 at which point the outstanding balance is due in full. The subordinated promissory notes may be prepaid by the Company at any time following the first anniversary thereof without penalty. The notes are subordinated to all indebtedness of the Company pursuant to the bank credit facility.

In connection with the subordinated promissory notes, the Company issued warrants to purchase the Company's common stock at \$3.51 per share. The warrants expire in December 2016. The proceeds were allocated between the notes and warrants on a relative fair value basis resulting in \$416,950 allocated to the notes and \$83,050 allocated to the warrants as part of Additional-Paid-in-Capital. The total discount on the notes is being recognized as non-cash interest expense over the term of the notes. The Company recorded \$6,921 for the three months ended March 31, 2016 and 2015 of non-cash interest expense related to the amortization of the discount. The unamortized discount which is net against the outstanding balance of the subordinated promissory notes is \$19,944 at March 31, 2016 and \$26,865 at December 31, 2015.

**7. Income Taxes**

No provision for income taxes has been recorded in the three months ended March 31, 2016 or 2015, respectively. The Company has a full valuation allowance against its deferred tax assets as of March 31, 2016 and December 31, 2015.

The Company has federal and state net operating loss carryforwards totaling \$8,196,000 and \$8,231,000, respectively, which begin to expire in 2030. The Company also had federal and state tax credit carryovers of \$361,000 and \$380,000 respectively. The federal and state tax credits begin to expire in 2029 and 2016, respectively.

**8. Commitments and Contingencies**

*Legal matters*

In the ordinary course of its business, the Company is involved in various legal proceedings involving a variety of matters. The Company does not believe there are any pending legal proceedings that will have a material impact on the Company's financial position or results of operations.

*Off-balance sheet arrangements*

The Company has two operating leases for office equipment. Lease expense under all operating leases was approximately \$1,822 for the three months ended March 31, 2016 and 2015.

**Arrhythmia Research Technology, Inc. and Subsidiaries**  
**Period Ended March 31, 2016**

Notes to the Condensed Consolidated Financial Statements (unaudited)

## 9. Stock Options and Share-Based Incentive Plan

### *Options*

The following table sets forth the stock option transactions for the three months ended March 31, 2016:

	Number of options	Weighted Average Exercise Price	Weighted average remaining contractual term (in years)	Aggregate Intrinsic Value
Outstanding at December 31, 2015	184,500	\$ 6.21	6.80	\$ 235,293
Granted	—	—		
Exercised	(15,000)	3.41		
Forfeited	—	—		
Expired	—	—		
Outstanding at March 31, 2016	169,500	6.46	7.15	\$ 186,843
Exercisable at March 31, 2016	73,500	\$ 7.33	5.74	\$ 58,115
Exercisable at December 31, 2015	83,500	\$ 6.60	4.73	\$ 106,565

For the three months ended March 31, 2016 and 2015, share-based compensation expense related to stock options amounted to \$15,133 and \$7,186, respectively, and is included in general and administrative expenses.

For the three months ended March 31, 2016, there were no new options granted and no options expired or were forfeited. There were 15,000 options exercised generating proceeds of \$51,150.

For the three months ended March 31, 2015, 25,000 options were granted, 7,500 options were forfeited and no options expired. Additionally, 1,100 options were exercised generating proceeds of \$3,880.

### *Warrants*

For the three months ended March 31, 2016 and 2015, there were no warrants exercised. As of March 31, 2016, 70,000 warrants remain unexercised.

## 10. Discontinued Operations

The Company's subsidiary, RMDDxUSA Corp. and its Prince Edward Island subsidiary RMDDx Corporation (collectively "WirelessDx"), discontinued operations 2012, filed for relief under Chapter 7 (Liquidation) of the United States Bankruptcy Code in 2014 and on March 20, 2015, the Chapter 7 Order was formally discharged and the case was closed.

For the three months ended March 31, 2015, net income of \$362,610 was recorded from discontinued operations as a result of the write-off of the remaining liabilities of \$320,056 and the reversal of accumulated other comprehensive income of \$42,553 from cumulative translation adjustments from RMDDx Corporation.

## Table of Contents

### Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

#### *Forward-Looking Statements*

This Quarterly Report on Form 10-Q contains forward-looking statements that involve a number of risks and uncertainties. There are a number of factors that could cause the Company's actual results to differ materially from those forecasted or projected in such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date hereof. The Company is under no obligation and does not intend to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of any unanticipated events. More information about factors that potentially could affect the Company's financial results is included in the Company's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2015.

#### *Critical Accounting Policies*

The critical accounting policies utilized by the Company in preparation of the accompanying financial statements are set forth in Part II, Item 7 of the Company's Annual Report on Form 10-K for the year ended December 31, 2015, under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations". There have been no material changes to these policies since December 31, 2015.

#### *Overview*

Arrhythmia Research Technology<sup>®</sup>, Inc., a Delaware corporation ("ART"), through its wholly-owned Massachusetts subsidiary, Micron Products<sup>®</sup>, Inc. ("Micron" and together with ART, the "Company"), is a diversified contract manufacturing organization ("CMO") that produces highly-engineered, innovative medical device components requiring precision machining and injection molding. The Company also manufactures components, devices and equipment for military, law enforcement, automotive and consumer product applications. The Company is engaged in the production and sale of silver/silver chloride coated and conductive resin sensors used as consumable component parts in the manufacture of integrated disposable electrophysiological sensors. These disposable medical devices are used worldwide in the monitoring of electrical signals in various medical applications. The Company's machining operations produce quick-turn, high volume and patient-specific finished orthopedic implant components. The Company has custom thermoplastic injection molding capabilities as well, and provides a full array of design, engineering, production services and management. The Company competes globally, with more than forty percent of its revenue derived from exports.

The Company's subsidiary, RMDDxUSA Corp. and its Prince Edward Island subsidiary RMDDx Corporation (collectively "WirelessDx"), discontinued operations in 2012, filed for relief under Chapter 7 (Liquidation) of the United States Bankruptcy Code in May 2014 and in March 2015, the Chapter 7 Order was formally discharged and the case was closed.

#### *Results of Operations*

The following table sets forth, for the periods indicated, the percentages of the net sales represented by certain items reflected in the Company's statements of operations.

	Three Months Ended			
	March 31,			
	2016	%	2015	%
Net sales	100.0		100.0	
Cost of sales	86.3		86.4	
Gross profit	13.7		13.6	
Selling and marketing	5.9		4.4	
General and administrative	13.9		11.1	
Research and development	0.5		1.6	
Other expense	1.2		0.9	
Income (loss) from continuing operations before income taxes	(7.8)		(4.4)	
Income tax provision	—		—	
Income (loss) from continuing operations	(7.8)		(4.4)	
Income from discontinued operations	—		6.2	
Net (loss) income	(7.8)	%	1.8	%

## Table of Contents

### *Net Sales*

The Company's consolidated net sales for the three months ended March 31, 2016 was \$4,983,281, a decrease of \$875,061, or 14.9%, when compared to the consolidated net sales of \$5,858,342 for the three months ended March 31, 2015. The decrease in net sales for the three months ended March 31, 2016 was due to a decrease in net sensor sales and net sales of orthopedic implant components, partially offset by increased sales of custom thermoplastic injected molding.

Net sales of sensors decreased 18.2% for the three months ended March 31, 2016 when compared to the same period last year. While sensor volume increased 12.6% over the same quarter last year, net sales decreased due to customer mix, product mix and the industry's continuing trend toward smaller parts. Silver surcharge billed decreased 24.1% due in part to the industry trend toward smaller parts and less silver as well as a 12.1% decrease in the weighted average price of silver for the three months ended March 31, 2016, as compared to the same period in 2015. Additionally, net sales of orthopedic implant components for the three months ended March 31, 2016 decreased 25.1% due to lower than expected volume from a large customer as compared to the same period in 2015, as well as product mix.

The decrease in net sales was partially offset by a 3.0% increase in net sales of custom thermoplastic injection molding for the three months ended March 31, 2016 as compared to the same period in 2015 due to increased order volume of medical and automotive components.

### *Gross Profit*

The Company's gross profit for the three months ended March 31, 2016 was \$685,119, a decrease of \$111,277, or 14.0%, when compared to gross profit of \$796,396 for the same period in 2015. Gross profit as a percentage of sales for the three months ended March 31, 2016 increased to 13.7%, or 0.1 points from 13.6% for the three months ended March 31, 2015.

The decrease in gross profit was due to a 35.2% decrease in gross profit from sensors which was due largely to price reductions as well as customer and product mix. Sensors gross profit as a percentage of sales decreased 4.9 points due primarily to the reduction in net sales and selling price. Additionally, gross profit from machined orthopedic implants decreased 19.6% largely due to lower volume combined with increased labor costs related to process validation efforts. However, machined orthopedic implants gross profit as a percentage of sales increased slightly, 1.2 points, due partly to product mix and improved efficiencies. Gross profit also decreased in part due to the timing of deferrals and the recognition of deferred revenue.

The decrease in gross profit was partially offset by a 7.7% increase in gross profit of custom thermoplastic injection molding for the three months ended March 31, 2016 when compared to the same period in 2015 due to increased demand of medical and automotive components. Custom thermoplastic injection molding gross profit as a percentage of sales increased 1.4 points due primarily to product mix. Also impacting gross profit was a decrease in expenses in the Quality and other manufacturing overhead departments as adjustments were made in part as a result of lower sales in the quarter. Quality and other manufacturing overhead expressed as a percentage of sales decreased to 8.9% for the three months ended March 31, 2016 as compared to 10.2% in the same period last year.

### *Selling and Marketing*

The Company's consolidated selling and marketing expenses amounted to \$293,346 (5.9% of net sales) for the three months ended March 31, 2016 as compared to \$257,972 (4.4% of net sales) for the three months ended March 31, 2015, an increase of \$35,374, or 13.7%. For the three months ended March 31, 2016, the increase was primarily due to increased wages, taxes and benefits of \$85,896 as a result of two additional salespersons hired in the fourth quarter of 2015. In addition, travel increased \$3,480 due to trade shows and customer relations. The increase was offset by a decrease in commissions of \$29,405 as a result of lower net sales as compared to the same period in the prior year and a decrease in marketing expenses of \$32,424.

### *General and Administrative*

The Company's consolidated general and administrative expenses increased to \$690,635 (13.9% of net sales) for the three months ended March 31, 2016 as compared to \$648,227 (11.1% of net sales) for the three months ended March 31, 2015 an increase of \$42,408, or 6.5%. The increase in general and administrative expenses is due primarily to \$51,600 of recruiting agency fees related to the replacement of three positions. Legal fees increased \$25,869 as compared to the prior year quarter. In addition, directors' fees increased \$20,000 as a result of adding two new Directors in 2015 and one in February 2016.

These increases were partially offset by decreased wages, taxes and benefits of \$25,780 due to the timing of replacement hires for three positions. In addition, consulting fees related to environmental, health and safety decreased \$21,500 due to bringing this function in house. Additionally accounting related expenses decreased \$14,211 due in part to savings realized from new SEC filing software. There were multiple smaller variances in computer supplies, bank fees, software expenses, stock based compensation and insurance on accounts receivable for the three months ended March 31, 2016 versus the same period in the prior year.

## Table of Contents

### ***Research and Development***

The Company's consolidated research and development expenses decreased to \$25,843 (0.5% of net sales) for the three months ended March 31, 2016 as compared to \$92,561 (1.6% of net sales) for the three months ended March 31, 2015, a decrease of \$66,718, or 72.1%. The decrease is due in part to decreased compensation of \$24,615 due to reorganization as well as a \$42,103 decrease in internal research and development costs for the development of new products and capabilities related to medical device components.

### ***Other Expense, net***

Other expense, net increased to \$59,443 for the three months ended March 31, 2016, as compared to \$52,184, for three months ended March 31, 2015, an increase of \$7,259. The increase in other expense was due to a gain on the sales of fixed assets of \$11,029 in 2015 versus no sales in 2016. In addition, interest expense decreased \$5,473 in 2016 as a result of continued pay down of term debt.

### ***Income Tax Provision***

The tax provisions for the three months ended March 31, 2016 and 2015 attributable to the U.S. federal and state income taxes on our continuing operations are zero. The Company's combined federal and state effective income tax rate from continuing operations for both the three months ended March 31, 2016 and 2015 of 0% is due to the deferred tax assets being fully reserved for with a valuation allowance.

### ***Income from Discontinued Operations***

The Company's subsidiary, RMDDxUSA Corp. and its Prince Edward Island subsidiary RMDDx Corporation (collectively "WirelessDx"), discontinued operations 2012, filed for relief under Chapter 7 (Liquidation) of the United States Bankruptcy Code in 2014 and on March 20, 2015, the Chapter 7 Order was formally discharged and the case was closed.

For the three months ended March 31, 2015 net income of \$362,610 was recorded from discontinued operations as a result of the write-off of the remaining liabilities of \$320,056 and the reversal of accumulated other comprehensive income of \$42,553 from cumulative translation adjustments from RMDDx Corporation.

### ***Earnings (Loss) Per Share***

Consolidated basic and diluted loss per share for the three months ended March 31, 2016 was \$0.14 per share as compared to basic and diluted earnings of \$0.04 per share for the same period in 2015, a decrease of \$0.18 per share. The decrease in earnings per share for the three months ended March 31, 2016, is due largely to the decreased gross profit in sensors.

The basic and diluted earnings per share for the three months ended March 31, 2015 were impacted by income from discontinued operations of RMDDxUSA which received relief under Chapter 7 of the United States Bankruptcy Code and was formally discharged in March 2015.

### ***Off-Balance Sheet Arrangements***

The Company has two operating leases for office equipment. Lease expense under all operating leases was approximately \$1,822 for the three ended March 31, 2016 and 2015, respectively.

### ***Liquidity and Capital Resources***

Working capital was \$2,520,332 as of March 31, 2016, as compared to \$2,509,588 at December 31, 2015, an increase of \$10,744. The increase is due primarily to an increase in accounts receivable, which is mostly offset by increases in accounts payable, accrued expenses and other current liabilities and customer deposits.

Cash and cash equivalents were \$220,299 and \$272,291 at March 31, 2016 and December 31, 2015, respectively, a decrease of \$51,992. Substantially all of these funds are maintained in bank deposit accounts.

Trade accounts receivable were \$3,339,549 and \$2,798,353 at March 31, 2016 and December 31, 2015, respectively, an increase of \$541,196 due in part to the timing of an increase in net sales for the month of March 2016 as compared to December 2015.

Inventories were \$2,115,071 at March 31, 2016, as compared to \$2,118,712 at December 31, 2015, a decrease of \$3,641.

Accounts payable increased \$118,143 due largely to the timing of disbursements.



## Table of Contents

Accrued expenses and other current liabilities increased \$98,993 as compared to December 31, 2015 due largely to an increase of \$79,461 for accruals for goods received not yet invoiced. Additionally, the Company accrued \$20,950 in the first quarter 2016 related to customer rebates and recorded increased legal accruals of \$17,536. These increases were partially offset by a \$25,685 reduction in accrued commissions.

Customer deposits increased \$266,255 due to an increase in tooling orders.

Capital equipment expenditures were \$373,259 for the three months ended March 31, 2016, due to investments in machinery and equipment primarily for the contract manufacturing of orthopedic implant components as well as injection molding equipment as compared to \$242,390 in the same period in 2015.

At March 31, 2016, the Company's total debt was \$4,363,865 as compared to \$4,031,767 at December 31, 2015, an increase of \$332,098 or 8.2% due primarily to a net increase of \$470,000 on the revolver. The total outstanding balance of the Company's term debt decreased \$144,823 to \$1,565,464 at March 31, 2016 as compared to \$1,710,287 at December 31, 2015. The Company also had a balance of \$336,850 on an equipment line of credit and \$480,056 of subordinated promissory notes as discussed in more detail below.

The Company has a multi-year credit facility with a Massachusetts bank. Under this credit facility the Company has a revolving line of credit (the "revolver"), commercial term loan, two equipment term loans and an equipment line of credit as detailed below. The bank facility contains both financial and non-financial covenants, all of which the Company is in compliance with at March 31, 2016.

The revolver provides for borrowings up to 80% of eligible accounts receivable and 50% of eligible raw materials inventory. The interest rate on the revolver is calculated at the bank's prime rate plus 0.25% (3.75% at March 31, 2016). The balance outstanding on the revolver was \$1,981,495 as of March 31, 2016. The revolver has a maturity date of June 30, 2017. Amounts available to borrow under the revolver are \$264,731 at March 31, 2016.

The commercial term loan has a five year term with a maturity date in March 2018. The interest rate on the loan is a fixed 4.25% per annum, and requires monthly payments of approximately \$28,000. At March 31, 2016, the balance of the commercial term loan was \$638,199.

The original equipment line of credit allowed for advances of up to \$1.0 million and included a one-year draw period during which payments were interest only. The draw period ended March 29, 2014 and the then outstanding balance on the equipment line of credit of \$740,999 was converted to a five-year term loan with monthly payments of approximately \$14,000 consisting of principal and interest at a fixed rate of 4.65%. The balance of this equipment term loan was \$465,368 as of March 31, 2016.

On June 26, 2014, the Company entered into an equipment line of credit that allowed for advances of up to \$1.0 million and included a one-year draw period during which payments were interest only. The draw period ended June 26, 2015 and the then outstanding balance on the equipment line of credit of \$415,785 was converted to an equipment term loan with a five-year term, maturing on of June 26, 2020. The equipment term loan requires monthly payments of approximately \$8,000, consisting of principal and interest at a fixed rate of 4.67% beginning in July 2015. The balance of this equipment term loan was \$359,625 as of March 31, 2016.

On June 19, 2015, the Company entered into a new equipment line of credit for \$1.0 million under the Company's multi-year credit facility. At March 31, 2016, \$336,850 has been drawn on the new equipment line of credit. The term of this equipment line of credit is six years, maturing on June 19, 2021, inclusive of a maximum one-year draw period. Repayment shall consist of monthly interest only payments, equal to the bank's prime rate plus 0.25% as to each advance commencing on the date of the loan through the earlier of: (i) one year from the date of the loan or (ii) the date upon which the equipment line of credit is fully advanced (the "Conversion Date"). On the Conversion Date, principal and interest payments will be due and payable monthly in an amount sufficient to pay the loan in full based upon an amortization schedule commensurate with the remaining term of the loan.

The borrowing agreement, under the bank facility as described above, contains both financial and non-financial covenants. The financial covenants include maintaining certain debt coverage and leverage ratios. The non-financial covenants relate to various matters including notice prior to executing further borrowings and security interests, mergers or consolidations, acquisitions, guarantees, sales of assets other than in the normal course of business, leasing, changes in ownership and payment of dividends. The Company is in compliance with all covenants at March 31, 2016.

In January 2013, the Company entered into two equipment notes totaling \$272,500 with a financing company to acquire production equipment. The notes bear interest at the fixed rate of 4.66% and require monthly payments of principal and interest of approximately \$5,000 over a five year term maturing in January 2018. The outstanding balance of these equipment notes at June 30, 2015 was \$102,272.

## Table of Contents

In December 2013, the Company completed a private offering in which the Company sold an aggregate of \$500,000 in subordinated promissory notes. The notes are unsecured and require quarterly interest-only payments at a rate of 10% per annum. On the second anniversary following issuance, the interest rate increases to 12% per annum. The notes mature in December 2016 at which point the outstanding balance is due in full. The subordinated promissory notes may be prepaid by the Company at any time following the first anniversary thereof without penalty. The notes are subordinated to all indebtedness of the Company pursuant to the bank credit facility.

In connection with the subordinated promissory notes, the Company issued warrants to purchase the Company's common stock at \$3.51 per share. The warrants expire in December 2016. The proceeds were allocated between the notes and warrants on a relative fair value basis resulting in \$416,950 allocated to the notes and \$83,050 allocated to the warrants as part of Additional-Paid-in-Capital. The total discount on the notes is being recognized as non-cash interest expense over the term of the notes. For the three months ended March 31, 2016 and 2015, the Company recorded \$6,921 of non-cash interest expense related to the amortization of the discount. The unamortized discount which is net against the outstanding balance of the subordinated promissory notes is \$19,944 at March 31, 2016 and \$26,865 at December 31, 2015.

No dividends were declared or paid in the three months ended March 31, 2016 and 2015.

The Company believes that cash flows from its operations, together with its existing working capital, the revolving line of credit and other resources, will be sufficient to fund operations at current levels and repay debt obligations over the next twelve months. The Company continues to develop opportunities within new and existing channels where the Company can maximize its return on investments in capital equipment, research and development, marketing and human resources.

### *Summary of Changes in Cash Position*

As of March 31, 2016, the Company had cash on hand of \$220,299. For the three months ended March 31, 2016, net cash used in operating activities was \$55,060. Net cash used in investing activities for the three months ended March 31, 2016 was \$373,259. Net cash provided by financing activities for the three months ended March 31, 2016 was \$376,327. All of the above were from continuing operations. The net cash flows for the three months ended March 31, 2016 are discussed in further detail below.

### *Operating Cash Flows*

For the three months ended March 31, 2016, net cash used in operating activities was \$55,060 due largely to the increase of \$541,196 in accounts receivable due to increased sales in March 2016 when compared to sales in December 2015, and the timing of accounts receivable collections.

This increase was offset by net cash provided by accrued expenses and other current liabilities which increased \$350,954 due in part to an increase of \$266,255 in customer deposits and an increase of \$79,461 for inventory received but not invoiced at March 31, 2016 as compared to December 31, 2015. Additionally, as of March 31, 2016, there was an increase in accounts payable of \$118,143. Cash provided by operating activities was also impacted by non-cash add-backs for depreciation and amortization of \$361,440, share-based compensation of \$15,133 and non-cash interest expense of \$6,921.

### *Investing Cash Flows*

For the three months ended March 31, 2016, net cash used in investing activities was \$373,259. The net cash used was for capital expenditures of \$373,259, largely for machinery and equipment, primarily for the contract manufacturing of orthopedic implant components as well as for molding equipment.

### *Financing Cash Flows*

For the three months ended March 31, 2016, net cash provided by financing activities was \$376,327. Cash was provided by net proceeds of \$470,000 from the Company's revolver and offset by payments on term notes payable of \$144,823. Additionally, there were proceeds of \$51,150 from the exercise of stock options.



## [Table of Contents](#)

### **Item 3. Quantitative and Qualitative Disclosures about Market Risk**

Not Applicable.

### **Item 4. Controls and Procedures**

#### *Evaluation of Disclosure Controls and Procedures*

Our principal executive officer and principal financial officer (“the Certifying Officers”) have evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)). Based on such evaluation, our Certifying Officers have concluded the Company's disclosure controls and procedures, as of the end of the period covered by this report, were effective.

The effectiveness of a system of disclosure controls and procedures is subject to various inherent limitations, including cost limitations, judgments used in decision making, assumptions about the likelihood of future events, the soundness of internal controls, and fraud. Due to such inherent limitations, there can be no assurance that any system of disclosure controls and procedures will be successful in preventing all errors or fraud, or in making all material information known in a timely manner to the appropriate levels of management.

#### *Changes in Internal Control over Financial Reporting*

During the three months ended March 31, 2016 there have been no changes in the Company's internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

## Table of Contents

### PART II - OTHER INFORMATION

#### Item 6. Exhibit Index

<u>Exhibit Number</u>	<u>Description of Exhibit</u>	<u>Page</u>
3.0	Certificate of Incorporation (incorporated by reference to the Company's Registration Statement on Form S-18 as filed with the Commission in April 1988, Registration Statement No. 33-20945-FW).	
3.1	Amended and Restated By-laws (incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K as filed with the Commission on July 1, 2011).	
3.2	Certificate of Amendment of Certificate of Incorporation (incorporated by reference to Exhibit 3.2 to the Company's Quarterly Report on Form 10-Q as filed with the Commission on August 13, 2015).	
4.0	Form of Certificate evidencing shares of the Company's Common Stock (incorporated by reference to the Company's Registration Statement on Form S-18 as filed with the Commission in April 1988, Registration Statement No. 33-20945-FW).	
4.6*	2001 Stock Option Plan (incorporated by reference to Exhibit 99.6 to the Company's Annual Report on Form 10-KSB for fiscal year ended December 31, 2001 as filed with the Commission on March 29, 2002).	
4.10*	2010 Equity Incentive Plan (incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-8 as filed with the Commission on May 6, 2010, Registration Statement No. 333-166600).	
4.11	Form of Subordinated Note (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K as filed with the Commission on December 23, 2013).	
4.12	Form of Subordination Agreement (incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K as filed with the Commission on December 23, 2013).	
4.13	Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K as filed with the Commission on December 23, 2013).	
10.50	First Amendment and Loan Modification dated as of March 11, 2013 between the Company and RBS Citizens, National Association and RBS Asset Finance, Inc. (incorporated by reference to Exhibit 10.50 to the Company's Quarterly Report on Form 10-Q as filed with the Commission on July 1, 2013).	
10.51	Loan and Security Agreement between UniBank for Savings and Arrhythmia Research Technology, Inc. and Micron Products, Inc. dated March 29, 2013 (incorporated by reference to Exhibit 10.51 to the Company's Quarterly Report on Form 10-Q as filed with the Commission on July 1, 2013).	
10.56*	Employment Agreement between the Company and Salvatore Emma, Jr. dated as of January 9, 2014 (incorporated by reference to Exhibit 10.56 to the Company's Quarterly Report on Form 10-Q as filed with the Commission on May 9, 2014).	
10.57*	Employment Agreement between the Company and Derek T. Welch dated as of January 9, 2014 (incorporated by reference to Exhibit 10.57 to the Company's Quarterly Report on Form 10-Q as filed with the Commission on May 9, 2014).	
10.58	Third Amendment to Loan and Security Agreement and Commercial Equipment Line of Credit Promissory Note dated June 26, 2014 (incorporated by reference to Exhibit 10.58 to the Company's Quarterly Report on Form 10-Q as filed with the Commission on August 7, 2014).	
10.59*	Employment Agreement between the Company and Salvatore Emma, Jr. dated as of January 20, 2015 (incorporated by reference to Exhibit 10.59 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 as filed with the Commission on March 20, 2015).	
10.60*	Employment Agreement between the Company and Derek T. Welch dated as of January 20, 2015 (incorporated by reference to Exhibit 10.60 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 as filed with the Commission on March 20, 2015).	
10.61	Fourth Amendment to Loan and Security Agreement and Commercial Equipment Line of Credit Promissory Note dated June 19, 2015 (incorporated by reference to Exhibit 10.61 to the Company's Quarterly Report on Form 10-Q as filed with the Commission on August 13, 2015).	
21	Subsidiaries (incorporated by reference to Exhibit 21.0 to the Company's Annual Report on Form 10-K for fiscal year ended December 31, 2010 as filed with the Commission on March 23, 2011).	
31.1**	Certification of the CEO pursuant to Rule 13a-14(a) or Rule 15(d)-14(a)	X-1
31.2**	Certification of the CFO pursuant to Rule 13a-14(a) or Rule 15(d)-14(a)	X-2
32.1**	Certification of the CEO pursuant to 18 U.S.C. §1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X-3

## Table of Contents

32.2**	Certification of the CFO pursuant to 18 U.S.C. §1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X-4
101.INS†	XBRL Instance Document	
101.SCH†	XBRL Taxonomy Extension Schema Document	
101.CAL†	XBRL Taxonomy Extension Calculation Linkbase Document	
101.PRE†	XBRL Taxonomy Extension Presentation Linkbase Document	
101.DEF†	XBRL Taxonomy Extension Definition Linkbase Document	

\*Indicates a management contract or compensatory plan required to be filed as an exhibit.

\*\*Filed herewith

† XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ARRHYTHMIA RESEARCH TECHNOLOGY, INC.

May 12, 2016

By: /s/ Salvatore Emma, Jr.

Salvatore Emma, Jr.

President and Chief Executive Officer

(principal executive officer)

By: /s/ Derek T. Welch

Derek T. Welch

Chief Financial Officer

(principal financial and accounting officer)